Lonza to Build Gene and Cell Therapies Facility in Houston
Lonza’s planned facility will be used to develop and manufacture viral gene therapies and virally modified cell therapies
Lonza announced on June 16 the planned construction of a 100,000-sq-ft facility for viral and immunotherapy development and manufacturing in the Houston, TX area. The new facility will more than double Lonza’s capacity for the production of viral gene and virally modified therapeutics and will include a segregated fill/finish suite, the company reports.
The multi-purpose facility is expected to come on-line in the first half of 2017 and will include eight independent cGMP modular cleanrooms for 2,000 L-scale production in single-use bioreactors. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. The site master plan includes expanded process development and quality-control areas, shell space for future additional cleanrooms, and land for further potential expansions.
Source: Lonza
